<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893564</url>
  </required_header>
  <id_info>
    <org_study_id>PI2019_843_0024</org_study_id>
    <nct_id>NCT04893564</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia</brief_title>
  <acronym>SLP-rares</acronym>
  <official_title>Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Lens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Waldenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration&#xD;
      and the presence of a monoclonal immunoglobulin M (IgM) in blood. This chronic&#xD;
      lymphoproliferative disorder requires treatment only in case of symptoms, according to&#xD;
      accurate criteria described during the second Workshop on WM i.e. in case of cytopenia, bulky&#xD;
      organomegaly, immunological or physicochemical consequences of the presence of IgM in&#xD;
      circulating blood. A MYD88 mutation, typically a MYD88(L265P), is found in 90% of WM&#xD;
      patients. Other gene abnormalities have been observed, the most frequent is a mutation in the&#xD;
      CXCR4 gene. Overall, gene mutations in WM involve only a limited number of signalling&#xD;
      pathways, yielding the activation of NFkB, namely : the TLR and MYD88 pathway (with an&#xD;
      activation of NFkB and BTK in case of MYD88(L265P) mutation), the BCR pathway (involving btk&#xD;
      and associated with activations of both NFkB, and erk akt pathway) and the CXCR4 pathway&#xD;
      (CXCR4 is a receptor of CXCL12, it is also associated with activations of ERK/MAPK and PI3K).&#xD;
      Abnormalities of some of genes, such as TP53, of the expression of the protein CXCL13 and&#xD;
      genes involved in the interleukin 6 secretion have been associated with some clinical&#xD;
      characteristics.&#xD;
&#xD;
      The purpose of this project is to define the prognostic role of the detection of circulating&#xD;
      tumoral DNA (ctDNA) at the end of treatment for the progression/relapse risk within the first&#xD;
      3 years after the first 6 months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>association between circulating tumoral DNA detection and progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>To define the prognostic role of the detection of circulating tumoral DNA (ctDNA) at the end of treatment for the progression/relapse risk within the first 3 years after the first 6 months of treatment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Waldenstrom's Disease</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bone marrow sample</intervention_name>
    <description>8 to 13 ml bone marrow sample for frozen storage within one of the 5 certified biobank of the canceropole area.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>20 ml blood sample for frozen storage within one of the 5 certified biobank of the canceropole area.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with WM according to diagnostic criteria&#xD;
&#xD;
          -  Patients with WM followed in one of the centre of North-Western region.&#xD;
&#xD;
          -  Patients requiring first-line or subsequent-line therapy&#xD;
&#xD;
          -  Patients agreement for giving informed consent.&#xD;
&#xD;
          -  Social insurance system affiliation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with another chronic B-cell malignancy&#xD;
&#xD;
          -  patients with other lymphoplasmacytic proliferations&#xD;
&#xD;
          -  patients with marginal zone lymphoma.&#xD;
&#xD;
          -  Patients with WM and histologic transformation&#xD;
&#xD;
          -  Absence of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre MOREL, MD</last_name>
    <phone>03.22.45.54.19</phone>
    <email>morel.pierre@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre MOREL, MD</last_name>
      <phone>03.22.45.54.19</phone>
      <email>morel.pierre@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice JARDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier TROUSSARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gandhi DAMAJ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie POULAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela ROBU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Waldenstrom's Disease</keyword>
  <keyword>Waldenstrom Macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

